5.90 USD
▼-0.40-6.35%
盘后 5.33 0.00%
2026-11-20
市值
$405.20M
市盈率
—
EPS
-7.00
股息率
—
52 周区间
3.64 – 24.91
成交量
9.33K
Beta
0.23
目标价
—
52W 低 3.6452W 高 24.91
价格走势
公司简介
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID pr...